Sign in or create an account to add this stock to your watchlist.
About Luminex (NASDAQ:LMNX)
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group B strep assays, ARIES group A strep assays, ARIES bordetella assays, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020
Debt
Debt-to-Equity RatioN/A
Current Ratio6.69
Quick Ratio5.20
Price-To-Earnings
Trailing P/E Ratio30.38
Forward P/E Ratio36.87
P/E Growth2.27
Sales & Book Value
Annual Sales$306.57 million
Price / Sales4.01
Cash Flow$1.41 per share
Price / Cash19.61
Book Value$10.28 per share
Price / Book2.69
Profitability
EPS (Most Recent Fiscal Year)$0.91
Net Income$29.42 million
Net Margins10.60%
Return on Equity8.07%
Return on Assets7.33%
Miscellaneous
Employees922
Outstanding Shares44,450,000
Luminex (NASDAQ:LMNX) Frequently Asked Questions
What is Luminex's stock symbol?
Luminex trades on the NASDAQ under the ticker symbol "LMNX."
How often does Luminex pay dividends? What is the dividend yield for Luminex?
Luminex announced a quarterly dividend on Friday, May 18th. Stockholders of record on Friday, June 22nd will be paid a dividend of $0.06 per share on Friday, July 13th. This represents a $0.24 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Thursday, June 21st. View Luminex's Dividend History.
How were Luminex's earnings last quarter?
Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings data on Monday, May, 7th. The medical instruments supplier reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.08. The medical instruments supplier earned $82.60 million during the quarter, compared to analysts' expectations of $80.52 million. Luminex had a return on equity of 8.07% and a net margin of 10.60%. Luminex's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.28 EPS. View Luminex's Earnings History.
When is Luminex's next earnings date?
What price target have analysts set for LMNX?
4 brokerages have issued 12-month target prices for Luminex's stock. Their forecasts range from $21.00 to $26.00. On average, they anticipate Luminex's share price to reach $23.00 in the next twelve months. View Analyst Ratings for Luminex.
Who are some of Luminex's key competitors?
Some companies that are related to Luminex include Haemonetics (HAE), Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), CryoLife (CRY), Cardiovascular Systems (CSII) and K2M Group (KTWO).
Who are Luminex's key executives?
Luminex's management team includes the folowing people:
- Mr. Nachum Shamir, CEO, Pres & Director (Age 64)
- Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 56)
- Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 50)
- Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 48)
- Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 56)
Has Luminex been receiving favorable news coverage?
News stories about LMNX stock have been trending positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Luminex earned a media sentiment score of 0.33 on Accern's scale. They also gave headlines about the medical instruments supplier an impact score of 46.06 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Luminex's major shareholders?
Luminex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.95%), Dimensional Fund Advisors LP (4.39%), Neuberger Berman Group LLC (2.60%), Millennium Management LLC (2.34%), Investment Management of Virginia LLC (2.21%) and Northern Trust Corp (2.15%). Company insiders that own Luminex stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.
Which major investors are selling Luminex stock?
LMNX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Neuberger Berman Group LLC, Alambic Investment Management L.P., Thomson Horstmann & Bryant Inc., Elk Creek Partners LLC, Blair William & Co. IL, American International Group Inc. and BNP Paribas Arbitrage SA. Company insiders that have sold Luminex company stock in the last year include G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Insider Buying and Selling for Luminex.
Which major investors are buying Luminex stock?
LMNX stock was purchased by a variety of institutional investors in the last quarter, including Hancock Holding Co., DAFNA Capital Management LLC, Dimensional Fund Advisors LP, Millennium Management LLC, Tamarack Advisers LP, Federated Investors Inc. PA, BlackRock Inc. and Great Lakes Advisors LLC. Company insiders that have bought Luminex stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex.
How do I buy shares of Luminex?
Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Luminex's stock price today?
One share of LMNX stock can currently be purchased for approximately $27.65.
How big of a company is Luminex?
Luminex has a market capitalization of $1.23 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe.
How can I contact Luminex?
Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]
MarketBeat Community Rating for Luminex (LMNX)
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Luminex (NASDAQ:LMNX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Luminex in the last 12 months. Their average twelve-month price target is $23.00, suggesting that the stock has a possible downside of 16.82%. The high price target for LMNX is $26.00 and the low price target for LMNX is $21.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.25 | 2.33 | 2.33 | 1.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $23.00 | $22.50 | $22.50 | $19.3333 |
| Price Target Upside: | 16.82% downside | 16.52% upside | 16.52% upside | 5.51% downside |
Luminex (NASDAQ:LMNX) Consensus Price Target History
Luminex (NASDAQ:LMNX) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Luminex (NASDAQ:LMNX) Dividend Information
Luminex pays an annual dividend of $0.24 per share, with a dividend yield of 0.87%. LMNX's next quarterly dividend payment will be made on Friday, July 13. Luminex pays out 26.37% of its earnings out as a dividend.
| Next Dividend: | 7/13/2018 |
| Annual Dividend: | $0.24 |
| Dividend Yield: | 0.87% |
| Payout Ratio(s): | 26.37% (Trailing 12 Months of Earnings)
32.00% (Based on This Year's Estimates)
29.63% (Based on Next Year's Estimates)
17.02% (Based on Cash Flow)
|
Luminex (NASDAQ:LMNX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/18/2018 | quarterly | $0.06 | 0.88% | 6/21/2018 | 6/22/2018 | 7/13/2018 |
| 1/24/2018 | Quarterly | $0.06 | 1.14% | 3/22/2018 | 3/23/2018 | 4/13/2018 |
| 12/14/2017 | quarterly | $0.06 | 1.18% | 12/21/2017 | 12/22/2017 | 1/12/2018 |
| 9/12/2017 | Quarterly | $0.06 | 1.2% | 9/21/2017 | 9/22/2017 | 10/13/2017 |
| 5/25/2017 | quarterly | $0.06 | 1.18% | 6/21/2017 | 6/23/2017 | 7/14/2017 |
| 2/22/2017 | special | $0.06 | | 3/22/2017 | 3/24/2017 | 4/14/2017 |
(Data available from 1/1/2013 forward)
Luminex (NASDAQ LMNX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 81.88%
Luminex (NASDAQ LMNX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/14/2018 | Todd C Bennett | SVP | Sell | 2,235 | $25.95 | $57,998.25 | 21,309 |  |
| 12/18/2017 | G Walter Loewenbaum II | Director | Sell | 10,503 | $20.61 | $216,466.83 | 564,217 | |
| 12/14/2017 | G Walter Loewenbaum II | Director | Sell | 31,739 | $20.49 | $650,332.11 | 574,720 | |
| 12/12/2017 | G Walter Loewenbaum II | Director | Sell | 39,456 | $20.40 | $804,902.40 | 651,736 | |
| 11/16/2017 | G Walter Loewenbaum II | Director | Sell | 50,000 | $21.79 | $1,089,500.00 | | |
| 8/23/2017 | Robert J Cresci | Director | Sell | 19,631 | $18.98 | $372,596.38 | 260,358 | |
| 5/30/2017 | G Walter Loewenbaum II | Director | Sell | 25,000 | $20.07 | $501,750.00 | 713,896 | |
| 5/23/2017 | G Walter Loewenbaum II | Director | Sell | 25,000 | $20.23 | $505,750.00 | 738,896 | |
| 5/18/2017 | G Walter Loewenbaum II | Director | Sell | 25,000 | $20.80 | $520,000.00 | | |
| 1/26/2017 | G Walter Loewenbaum II | Director | Sell | 20,000 | $19.75 | $395,000.00 | 766,240 | |
| 1/19/2017 | G Walter Loewenbaum II | Director | Sell | 20,000 | $19.82 | $396,400.00 | 766,240 | |
| 1/12/2017 | G Walter Loewenbaum II | Director | Sell | 20,000 | $20.43 | $408,600.00 | 766,240 | |
| 1/5/2017 | G Walter Loewenbaum II | Director | Sell | 20,000 | $20.32 | $406,400.00 | 766,240 | |
| 12/29/2016 | G Walter Loewenbaum II | Director | Sell | 20,000 | $20.27 | $405,400.00 | 766,240 | |
| 11/28/2016 | G Walter Loewenbaum II | Director | Sell | 50,000 | $20.57 | $1,028,500.00 | 749,414 | |
| 11/15/2016 | Kevin M Mcnamara | Director | Sell | 12,000 | $21.03 | $252,360.00 | 67,274 | |
| 11/3/2016 | Harriss T. Currie | SVP | Buy | 4,100 | $18.20 | $74,620.00 | | |
| 11/3/2016 | Nachum Shamir | CEO | Buy | 6,000 | $18.22 | $109,320.00 | 105,010 | |
| 1/4/2016 | G Walter Loewenbaum II | Director | Sell | 41,056 | $20.53 | $842,879.68 | 788,583 | |
| 12/31/2015 | G Walter Loewenbaum II | Director | Sell | 18,944 | $21.65 | $410,137.60 | 829,639 | |
| 12/16/2015 | Russell W. Bradley | CMO | Sell | 6,514 | $22.75 | $148,193.50 | 104,067 | |
| 5/28/2015 | Nachum Shamir | CEO | Buy | 6,000 | $16.73 | $100,380.00 | | |
| 5/27/2015 | G Walter Loewenbaum II | Director | Buy | 38,966 | $16.71 | $651,121.86 | | |
| 2/5/2015 | Fred C Goad Jr | Director | Sell | 25,000 | $15.46 | $386,500.00 | | |
| 10/8/2014 | Russell W Bradley | SVP | Sell | 5,000 | $20.50 | $102,500.00 | | |
| 5/15/2014 | Patrick Balthrop | CEO | Sell | 70,000 | $17.69 | $1,238,300.00 | 486,367 | |
| 5/12/2014 | Kevin Mcnamara | Director | Sell | 5,000 | $17.95 | $89,750.00 | 60,614 | |
| 5/9/2014 | Jim Kever | Director | Sell | 5,000 | $17.52 | $87,600.00 | 187,745 | |
| 5/7/2014 | Patrick Balthrop | CEO | Sell | 32,575 | $17.63 | $574,297.25 | 556,367 | |
| 5/6/2014 | Patrick Balthrop | CEO | Sell | 60,000 | $18.28 | $1,096,800.00 | 545,833 | |
| 5/2/2014 | Fred Goad, Jr. | Director | Sell | 50,000 | $18.86 | $943,000.00 | 312,745 | |
| 5/2/2014 | Patrick Balthrop | CEO | Sell | 55,000 | $19.05 | $1,047,750.00 | 524,937 | |
| 5/1/2014 | David Reiter | SVP | Sell | 15,000 | $19.09 | $286,350.00 | 60,400 | |
| 5/1/2014 | Harriss Currie | CFO | Sell | 11,000 | $19.08 | $209,880.00 | 186,576 | |
| 9/23/2013 | Harriss Currie | CFO | Sell | 30,000 | $19.88 | $596,400.00 | 167,748 | |
| 9/17/2013 | Harriss Currie | CFO | Sell | 30,000 | $19.87 | $596,100.00 | 167,748 | |
| 9/13/2013 | Michael Pintek | SVP | Sell | 3,000 | $20.00 | $60,000.00 | 54,392 | |
| 8/30/2013 | G Walter Loewenbaum II | Director | Buy | 6,034 | $20.62 | $124,421.08 | 864,662 | |
| 8/28/2013 | G Walter Loewenbaum II | Director | Buy | 20,000 | $20.76 | $415,200.00 | 858,628 | |
| 8/16/2013 | Timothy Dehne | VP | Sell | 32,297 | $20.66 | $667,256.02 | 20,441 | |
| 8/15/2013 | G Walter Loewenbaum II | Director | Buy | 10,000 | $20.82 | $208,200.00 | 838,628 | |
| 8/14/2013 | Timothy Dehne | VP | Sell | 1,793 | $21.21 | $38,029.53 | 20,441 | |
| 8/9/2013 | G Walter Loewenbaum II | Director | Buy | 4,600 | $21.17 | $97,382.00 | 828,628 | |
| 8/2/2013 | G Walter Loewenbaum II | Director | Buy | 27,000 | $20.01 | $540,270.00 | 823,628 | |
| 8/2/2013 | Patrick J Balthrop | CEO | Sell | 68,048 | $20.01 | $1,361,640.48 | | |
| 8/1/2013 | David S Reiter | SVP | Sell | 15,000 | $20.00 | $300,000.00 | | |
| 8/1/2013 | Thomas W Erickson | Director | Sell | 20,000 | $20.00 | $400,000.00 | | |
| 5/24/2013 | Fred C Goad Jr | Director | Buy | 11,250 | $18.25 | $205,312.50 | | |
| 5/17/2013 | G Walter Loewenbaum II | Director | Buy | 13,000 | $18.37 | $238,810.00 | 791,628 | |
| 5/16/2013 | Fred C Goad Jr | Director | Buy | 8,000 | $18.18 | $145,440.00 | | |
| 5/15/2013 | G Walter Loewenbaum II | Director | Buy | 39,500 | $18.32 | $723,640.00 | | |
| 5/10/2013 | David S Reiter | SVP | Sell | 10,000 | $18.26 | $182,600.00 | | |
| 5/10/2013 | G Walter Loewenbaum II | Director | Buy | 19,000 | $18.13 | $344,470.00 | | |
| 5/9/2013 | G Walter Loewenbaum II | Director | Buy | 28,300 | $17.21 | $487,043.00 | | |
| 5/7/2013 | G Walter Loewenbaum II | Director | Buy | 64,935 | $17.17 | $1,114,933.95 | | |
| 5/3/2013 | G Walter Loewenbaum II | Director | Buy | 24,765 | $17.02 | $421,500.30 | | |
| 9/4/2012 | David S Reiter | VP | Sell | 10,000 | $20.00 | $200,000.00 | | |
(Data available from 1/1/2013 forward)
Luminex (NASDAQ LMNX) News Headlines
| Source: |
|
Luminex (NASDAQ:LMNX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Luminex (NASDAQ:LMNX) Income Statement, Balance Sheet and Cash Flow Statement
Luminex (NASDAQ LMNX) Stock Chart for Thursday, May, 24, 2018
Loading chart…
